Inflammation‐related genetic modifiers have also been shown to influence the risk of developing neurodegenerative disorders such as sporadic AD, and this includes the triggering receptor expressed on myeloid cells 2 (TREM2)27, 28, 29, 30, 31, 32, 33 and toll‐like receptor 4 (TLR4).34, 35, 36 We therefore sought to investigate this in HD using both postmortem studies and clinical data from a large cohort of patients. The gene discussed is TREM2; the disease is Huntington disease.